Biogen will not offer early access to tofersen, its experimental therapy for familial amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, at least until data from its pivotal clinical trial are analyzed. Now in its Phase 3 portion, the study (NCT02623699) is testing the…
Retrotope has dosed the first patients in its recently-initiated Phase 2 clinical trial evaluating RT001 for the treatment of amyotrophic lateral sclerosis (ALS). Enrollment is open across four European sites for patients ages 20–75 whose disease symptoms began less than three years ago and do not need…
Roche Canada’s Artificial Intelligence Centre of Excellence (AI CoE), in collaboration with Answer ALS and EverythingALS, opened a challenge that asks the global artificial intelligence (AI) community to model solutions for key questions in amyotrophic lateral sclerosis (ALS). Called End ALS Challenge, the digital competition also…
Note: This story was updated March 31, 2021, to note that the ALSummit trial has been approved by the U.S. Food and Drug Administration but will proceed only in Korea; there are no plans to open additional sites in the U.S. or elsewhere. A Phase 3 clinical trial is…
A new feature of Cox’s accessible web remote enables people with amyotrophic lateral sclerosis (ALS) and others with disabilities to control their TVs using their eyes. The free remote also can be used with other assistive technologies, such as sip-and-puff. “We are committed to improving our products to…
To honor the memory of Broadway actor and singer Rebecca Luker, who died of complications due to amyotrophic lateral sclerosis (ALS) last year, Target ALS will present a live-streamed concert on May 4. All proceeds will go to support ALS research, the nonprofit group announced. The show, called “Becca,”…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Early treatment with Radicava (edaravone) significantly lowers the cumulative risk of death, need for mechanical and permanent ventilation,…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Long-term treatment with AMX0035 significantly lowers the risk of death, and the need for permanent ventilation and hospitalization…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. WVE-004, an investigational treatment for people with amyotrophic lateral sclerosis…
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Amyotrophic lateral sclerosis (ALS) patients living in the Midwest — the U.S. region with the highest ALS frequency —…
Get regular updates to your inbox.
